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Shank proteins (Shank1, Shank2, and Shank3) act as scaffolding molecules in the postsynaptic density of many excitatory neurons.
Mutations in SHANK genes, in particular SHANK2 and SHANK3, lead to autism spectrum disorders (ASD) in both human and
mousemodels. Shank3 proteins are made of several domains—the Shank/ProSAPN-terminal (SPN) domain, ankyrin repeats, SH3
domain, PDZ domain, a proline-rich region, and the sterile alpha motif (SAM) domain. Via various binding partners of these
domains, Shank3 is able to bind and interact with a wide range of proteins including modulators of small GTPases such as RICH2,
a RhoGAP protein, and 𝛽PIX, a RhoGEF protein for Rac1 and Cdc42, actin binding proteins and actin modulators. Dysregulation
of all isoforms of Shank proteins, but especially Shank3, leads to alterations in spine morphogenesis, shape, and activity of the
synapse via altering actin dynamics. Therefore, here, we highlight the role of Shank proteins as modulators of small GTPases and,
ultimately, actin dynamics, as found inmultiple in vitro and in vivomodels.The failure tomediate this regulatory role might present
a shared mechanism in the pathophysiology of autism-associated mutations, which leads to dysregulation of spine morphogenesis
and synaptic signaling.
1. Introduction
Like other eukaryotic cells, neurons have an extensive net-
work of cytoskeletons. Among them, actin is a key player
in the development of neurons and maintenance of neu-
ronal physiology. In developing neurons, actin provides the
structural network for morphogenesis. In adult neurons,
actin participates in the formation and dynamics of pre- and
postsynaptic structural integrity [1]. Therefore, it is not a
surprise that, in many neurodevelopmental and neurodegen-
erative disorders, actin structure and dynamics are altered.
For example, in case of autism spectrum disorders (ASD),
a dysregulation of scaffolding proteins as well as receptors,
signaling molecules, small GTPases, and actin dynamics
in the postsynaptic density (PSD) is observed [2]. Shank
(SH3 domain and ankyrin repeat containing protein) pro-
teins (alternatively known as ProSAP, proline-rich synapse
associated protein), a family comprised of 3 members, are
major scaffolding proteins found in PSDs of many excitatory
(mainly vGluT1 positive) synapses [3] and have been associ-
ated with ASD [4]. Mutation or deletion of Shank proteins
leads to alteration in NMDA and AMPA receptor trafficking,
actin remodeling, and/or alteration in synaptic signaling, in
particular mGluR5 signaling, in several in vitro and mouse
models [5]. In this review, we will focus on the effect of Shank
mutation and/or deletion on synaptic spine morphology via
altering actin remodeling. Interestingly, several interaction
partners of Shank proteins are able to alter the spine and
actin dynamics. The dysregulation of this Shank interacting
complex may be a factor shared between different disease-
associated mutations found in Shank3 and explain some of
the synaptic phenotypes observed across different mouse
models for Shankopathies. Overall, this review highlights
the role of Shank in synaptic actin signaling using different
signaling molecules in health and disease.
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Figure 1: Formation of filamentous actin. Monomeric G actin can
exchange GDP with GTP, depending on the energy status of the
cell. Such GTP bound actin proteins are more stable and can form
oligomers using weak noncovalent interactions. Such oligomers
serve as nucleus for further oligomerization. Actin binding proteins
(ABPs) can accelerate this process. Once oligomerized, the structure
has polarity for adding new activated monomers. The (+) end
can elongate the filamentous structure via adding new monomers,
whereas on the (−) end the GTP bound actin is converted to
GDP bound stage and dissociates from the filament. Such actin
tread milling is a key component in regulation of cellular structure,
morphogenesis, and activity.
2. Actin Dynamics at Synaptic Terminals
2.1. Basic Actin Dynamics. Actin is a 42 kDa protein which
can remain in two states—monomeric G (globular) actin
and polymeric F (filamentous) actin. At any given time,
some monomeric G actins exchange their ADP with ATP,
thereby creating stable G actin oligomers via weak nonco-
valent interactions. Such oligomers act as an actin nucleus.
The actin nucleus is a stable form of multimeric G actins.
Formation of an actin nucleus is the rate-limiting step in
the polymerization of actin since actin dimer intermediates
are very unstable and addition of actin monomers to the
nucleus may be prevented by actin monomer sequestering
proteins [6]. Some other proteins can also work as nucleation
factor such as Arp2/3. The actin nucleation center is a polar
oligomer, where more actin monomers can bind with the
(+) or “barbed end.” The barbed end acts as site for the
biochemical reactions necessary for addition of monomers.
In a cellular context, actin monomers are excess. Because of
the abundance, there is no direct competition for monomers
between different actin filaments at any given time.Therefore,
the ongoing dynamics at the barbed end are crucial for
regulation of actin polymerization, and a wide range of
proteins are associated with this process. For example, some
of these proteins act as capping proteins, which bind with
the barbed end and prevent further addition of an actin
monomer to that end [7]. On the other hand, at the (−) or
“pointed end,” theATP is hydrolyzed andmonomericG actin
leaves the nucleus in its ADP bound state. Such addition and
deletion of monomers create “actin tread milling” in the cell
(Figure 1). Depending on the energy state in the cell, the actin
can form protrusions at any certain direction or maintain
a certain structure. Using this mechanism, actin can also
create polarity in the cell structure, alter cellular morphology,
transport organelles, participate in vesicle trafficking, and,
overall, participate in signal transduction.
Besides forming filamentous structures, actin monomers
can bind with many other proteins (ABPs, or actin binding
proteins) in order to form higher cross-linking structures or
modify the stability of different ends. For example, alpha-
actinin assists monomeric G actins to cross-link with each
other. EPS8 (epidermal growth factor receptor pathway
substrate 8) and Gelsolin can cap the barbed end, thereby
stabilizing it. Some proteins can also destabilize actin poly-
mers like cofilin [8–10]. Several toxins have been isolated
from microorganism that can influence dynamics of actin.
Phalloidin, for example, can bind with F actin and enhances
polymerization, whereas cytochalasins bind with the barbed
end to prevent the addition of monomers [11].
2.2. Actin in Presynaptic Terminals. Upon neuronal activa-
tion, neurotransmitters are released from the axon of the
presynaptic neurons in the synaptic cleft.This happens via the
exocytosis of synaptic vesicles at the active zone. The process
of exocytosis requires calcium signaling and is achieved via
several steps: docking of the synaptic vesicle to the active
zone, assembly and maturation of the fusion machinery,
calcium influx triggered by action potentials, and finally the
fusion event [12]. Actin is abundant in the presynaptic protein
pool and performs very active roles in vesicle trafficking [13–
15]. It can restrict or enhance the mobility of the synaptic
vesicles. At the presynaptic bouton, actin can bind with
synapsin, which is phosphorylated in case neuronal activity
increases (Figure 2). This actin-synapsin-vesicle interaction
is very crucial for the organization of vesicles between the
reserve pool and the readily releasable pool [16–19]. Through
this and other mechanisms, actin can mediate synaptic
efficiency. For example, actin can facilitate vesicle release
from the bouton by modification of bouton size and vesicle
recycling after exocytosis that requires rapid actin turnover
[20].
Despite being a postsynaptic protein, Shank3 may indi-
rectly also affect the presynaptic actin-synapsin signal-
ing pathway mediated by transsynaptic activity involving
neurexin-neuroligin protein complexes [21]. Shank3 can
interact with the cytoplasmic tail of neuroligin 3 [22]. Neu-
roligin 3 is a postsynaptic protein that interacts with neurexin
in the presynaptic neuron and, together, they have an effect on
synapticmorphogenesis [23–25]. An increase in postsynaptic
Shank3 levels results in increased synapsin concentrations at
the presynapse [21]. Mutations in Shank3 affect the neurexin-
neuroligin transsynaptic pathway. Additionally, recently it
has been published that Shank mRNA and protein can be
detected on the axonal terminal of the neuronal growth cone
colocalizing with various presynaptic proteins there [26].
Thus, during early neuronal development, it is possible that
Shank3 also acts directly on actin signaling in the presynapse.
2.3. Actin in Postsynaptic Dendritic Spines. Actin has pivotal
role in the structure, function, and plasticity of the postsynap-
tic terminal. Actin remodeling is essential in various aspects
of postsynaptic signaling efficiency, ranging from receptor
anchoring and trafficking to dendritic spine formation. First
of all, actin can bind with scaffolding proteins in the PSD
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Figure 2: Actin in the presynaptic bouton. Actin performs a
crucial role in the vesicle trafficking, starting from docking of
the vesicle to neurotransmitter release. A special actin binding
protein, synapsin, assists actin in this regard. Synapsin can bind
with filamentous actin, and together they provide the supportive
network for vesicle release. Shank3 can bind with the C-terminal
tail of neuroligin 3 and thereby is able to modify the presynaptic
signaling via transsynaptic neuroligin-neurexin pathways. Synaptic
activity increases the amount of Shank3 in the PSD, which leads
to a coordinated increase in presynaptic synapsin. Further, during
neuronal development, Shank3 can also be located presynaptically,
thereby directly influencing actin dynamics there.
and thus can anchor receptors [27]. In fact, actin can anchor
AMPA andNMDA receptors on the surface of the postsynap-
tic dendritic spine as well as reducing the number of clusters
of gephyrin in inhibitory synapses [28, 29]. Therefore, actin
has the potential to influence the balance between inhibitory
and excitatory signals, which is a dominant feature of synaptic
processing. It has been shown that actin is found in different
pools at the postsynapse, and actin dynamics and turnover
can be regulated via synaptic signaling [30]. Ultimately,
by modulating spine morphology, actin stabilization and
depolymerization have, among others, different effects on the
AMPA and NMDA receptor population [31].
3. Shank3/Actin in Dendritic Spinogenesis
Dendritic spines are tiny protoplasmic protrusions on the
surface of dendrites and are the key receiver of excitatory
stimulations in neurons. Dendritic spines can vary a lot in
terms of their shape and synaptic transmission efficacy. Usu-
ally, mature spines are “mushroom” shaped with a thin neck
and much larger head, while immature spines are thinner
protrusions with no clear head and harboring small PSDs.
Immature spines are called “filopodia-like” and “thin” spines.
Such morphological diversity may arise from development
and neuronal activity but is also influenced by pathological
conditions [32]. Under normal circumstances, bigger spines
have larger PSD areas, and the greater the area, the more
the receptors located at the PSD. The main cytoskeletal
component of the dendritic spine is actin, especially in the
PSD where complex organization of receptors, scaffolding
molecules, and actin occurs [1]. Based on the turnover rate,
cellular actin can be subdivided into two pools—dynamic
actin and stable actin. Upon stimulation, there is a possibility
of rapid remodeling of the dynamic actin pool [33]. It has
been shown that long-term potentiation (LTP) favors the
shift of the G/F actin equilibrium towards F actin and thus
can increase the size of the spine head. This happens in
three stages: first there is the immediate reorganization of
the actin cytoskeleton within the spine; then, newly formed
structures are stabilized; and, finally, PSD scaffolding proteins
are recruited to the modulated PSD to stabilize receptors
[34]. The last stage is dependent on protein synthesis to
some extent. In case of long-term depression (LTD), the
equilibrium shifts towards monomeric G actin and the size
of the spine head is reduced [35, 36].
There is heterogeneity in the distribution of NMDA and
AMPA receptors on the dendritic spine. NMDA receptors are
abundant on spines irrespective of theirmorphology, whereas
AMPA receptors are mostly present on larger excitatory
spines. Therefore, it can be hypothesized that most small
spines are “silent,” due to the Mg2+ blocking of NMDA
receptors, in terms of the response towards excitatory signals;
larger, mature spines can receive and enhance such inputs
in much more efficient way [37]. This indicates that both
the morphology of the spine and number of receptors at
the PSD can be altered in response to synaptic signaling via
actin remodeling (Figure 3). The modification of the actin
cytoskeleton upon synaptic activity is realized by a signaling
complex that transforms synaptic activity into activation of
postsynaptic pathways. Here, Shank3 and small GTPases are
in the focus.
Shank proteins were originally identified in the rat hip-
pocampus in the 1990s [38, 39]. They are relatively large
multiple domains proteins with more than 2000 residues and
about 200 kDa in molecular mass. Because of the presence
of many domains, Shank proteins are able to interact with
many other synaptic proteins. Additionally, due to the SAM
domain, Shank2 and Shank3 are sensitive to local zinc
signaling [40–42]. It has been shown that the position of
Shank is in the deeper part of PSD, probably below the PSD-
95 scaffold [43].
Three isoforms of the Shank proteins have been identified:
Shank1, Shank2, and Shank3 [44]. Different isoforms share
63–87% homology in their sequences. In adult rat, Shank1
is only expressed in the brain, Shank2 is expressed in brain,
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Figure 3: Activity dependent spine morphology alteration. Upon
synaptic activation or in case of LTP, rapid actin remodeling favors
the formation of filamentous or F actin. This can have twofold
effects: one is the spine enlargement and the other one is that
actin is able to anchor additional receptors at the PSD. On the
other hand, synaptic depression or LTD is often coupled with spine
shrinkage. This is realized by the depolymerization of F actin. In
addition to such depolymerization, the number of receptors may
be decreased, thus making the dendritic spine less responsive to
synaptic stimulation. The changes in actin remodeling and receptor
trafficking can occur together or independent of each other. Spine
shrinkage and enlargement also depend on scaffolding proteins of
the Shank family that increase in number at the PSD upon LTP and
decrease upon LTD.
kidney, and liver, and Shank3 is predominantly expressed in
brain, spleen, and heart [45]. In the brain, Shank1 is expressed
in hippocampus, cortex, amygdala, substantia nigra, and
thalamus, but not in cerebellum, caudate nucleus, and corpus
callosum [46]. Shank2 and Shank3 share a common expres-
sion in different brain regions, including hippocampus and
cortex. But, in cerebellum, Shank2 is expressed in Purkinje
cells, whereas Shank3 is expressed in granular cell layer [47].
The various domains of Shank proteins interact with
different PSD proteins and thus can link with NMDA
and AMPA receptors, metabotropic glutamate receptors
(mGluRs), and actin [48, 49]. It has been shown that all
the Shank isoforms, Shank1, Shank2, and Shank3, upon
overexpression, induce the early maturation of spines in
young developing neurons [50]. In adult matured neurons,
Shank1 overexpression increases the size of the spines [50].
3.1. Regulation of Small GTPases and Actin. The large super-
family of small GTPases consists of five subfamilies: Ras, Rho,
GDI
GAP
GEF
GTP GDP
Small
GTPase
Small
GTPase
Effector
proteins
GTP GDP
GTP GDP
+Pi
Figure 4: Small GTPases act like amolecular switch. Small GTPases
are active when they are GTP bound and inactive when they
are GDP bound. The switch between active and inactive state is
mediated bymodulators, mainly GAPs (GTPase activating proteins)
and GEFs (guanosine exchange factors). GAP hydrolyzes the bound
GTP to GDP and GEF exchanges the GDP with GTP. Besides
GAPs and GEFs, there is another kind of modulators—GDI (GDP
dissociation inhibitors).
Rab, Sarl/ARF, and Ran. These small GTPases are involved
in a very diverse array of cellular actions ranging from
cytoskeletal rearrangements, cellular motility, and adhesion
to cellular division. Most of the studies involving small
GTPases are done in nonneuronal cells. However, in the
arena of dendritic spine morphogenesis, members of the
Rho and Ras superfamily exhibit very distinct functions
compared to other family members [51]. There are at least
14 members in the Rho family. Among them, Rac1 (Ras-
related C3 botulinum toxin substrate 1) and RhoA (Ras
homolog gene family, member A) are themost studied family
members. In dendritic spine morphogenesis, Rac1 and RhoA
have opposite effects [52, 53].
Small GTPases can act as molecular switch. They are
turned “on” when bound with GTP and “off” when bound
with GDP. GTPase modulators such as GEFs (guanosine
exchange factors) and GAPs (GTPase activating proteins)
mediate this switch (Figure 4). GEF activates the small
GTPase whereas GAP enables the small GTPase to go back
in the “off” state. Besides GEFs and GAPs, there is another
kind of modulators, GDI (guanosine nucleotide dissociation
inhibitors). When small GTPases are GDP bound and inac-
tive, then GDI proteins sequester them in the cytoplasm [54].
Overexpression of Rac1 leads to maturation of spines,
whereas overexpression of RhoA leads to spine loss [55]. The
downstream effectors of Rac1 are PAK (p21 activated kinase),
LIMK1 (LIM kinase 1), and actin binding protein cofilin
[56, 57]. Interacting with these proteins, Rac1 stabilizes F
actin.Themain downstream effector of RhoA is ROCK (Rho
associated protein kinase). Interestingly, ROCK can regulate
the activity of LIMK1 via controlling its phosphorylation
[58]. Cdc42 (cell division control protein 42) is a Rac
related GTPase and effects of Cdc42 in terms of dendritic
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spine morphology are similar to Rac1. Besides the effect
on postsynaptic spine morphology, the transformation of
immature axonal boutons to mature boutons requires actin
polymerization mediated via BDNF and Cdc42 activation
[59].
Since the activity of small GTPases depends on their
modulators, inhibition or deletion of the modulators in
turn can affect small GTPase signaling. RhoA is mostly
associated with spine shrinkage and actin destabilization.
GEFs that activate RhoA such as RhoA GEF H1 therefore
have similar effect and regulate spine density and length
negatively [60]. Several GEFs for Rac1 have been studied
extensively. However, in the cortex of adult mice, Kalirin-
7 is the only expressed Rac1 GEF [61]. Overexpression
and knock-down of Kalirin-7 have very clear-cut opposite
effects on spine morphogenesis: overexpression increases
spine density and head area, whereas RNAi mediated knock-
down reduces both [61–63]. In hippocampus, besides Kalirin-
7, two other Rac1 GEFs are expressed: Tiam1 and 𝛽PIX.
Tiam1 interacts with NMDA receptors, and NMDA receptor
activation can induce Tiam1 phosphorylation in a calcium
dependentmanner that activates actin remodeling dependent
on Rac1 signaling in dendritic spines [64].
Besides GEFs, some GAP modulators are also well char-
acterized in the central nervous system (CNS). Loss of the
RhoGAP protein Oligophrenin 1 disrupts spine and synapse
maturation [65]. Loss of the RhoGAP protein RICH2 leads to
increased activation of Rac1 and Cdc42 and increases spine
area in mouse model [66]. SynGAP1, a Ras GAP, can regulate
spine morphology via its effect on Rho GTPase and cofilin
[67].
Small GTPases can affect actin binding proteins directly.
They can relieve the autoinhibition of WASP (Wiskott-
Aldrich syndrome protein), which binds to both filamentous
and monomeric actin [68]. Along with Arp2/3 (actin related
protein2/3) and Cdc42, WASP can form a protein complex
that modulates actin assembly [69, 70]. Therefore, Arp2/3
serve as downstream signaling proteins of small GTPases and
WASP.
3.2. Shank and Spine Morphogenesis via Actin Regulation.
Mutations in SHANK have very clear-cut effect on synapto-
genesis and Shank can recruit other synaptic proteins such
as Homer1, which results in alterations of spine morphology
[50]. Shanks can bind NMDA receptors via PSD-95/GKAP
and mGluRs via Homer1 [50]. Both PSD-95 and GKAP are
involved in activity dependent spine growth [71]. Another
interaction partner of Shank proteins is cortactin. Shank
knock-down reduces both cortactin and actin in the spine in
cultured rat hippocampal neurons [72].
Further, in an interactome study, it was found that Shank3
directly interacts with Arp2/3 [73]. This is a direct link
between actin remodeling and Shank3. The first step of actin
polymerization is the decapping of the barbed end of actin
filaments so that the filament can be exposed for further
addition of G actin.The Arp2/3 complex helps in this regard.
The Arp2/3 complex consists of seven subunits including
two actin related proteins—Arp2 and Arp3 [74]. The Arp2/3
complex lowers the affinity of capping proteins for barbed
ends [75], which enables decapping, and further monomers
can be added to the filament. Additionally, Arp2/3 helps to
create complex multibranched actin filaments.The activity of
Arp2/3 can be further enhanced by other NPFs (nucleation
promoting factors). Two such NPFs are WASP (Wiskott-
Aldrich syndrome protein) and SCAR/WAVE (suppressor of
cAMP receptor/WASP family verprolin homologs). WASP
can bindwith Cdc42 in aGTP-dependentmanner [76]. Small
actin nuclei first bind with WASP; then Arp2/3 joins the
WASP-actin complex, facilitating decapping of the barbed
end. Subsequently, additional actin monomers can bind
with that end and the filament size is increased. Once the
filamentous actin is formed, then cortactin replaces WASP
and stabilizes the filamentous actin structure [77].Thus, using
Arp2/3 and cortactin, Shank3 is able to stabilize F actin and
enhance spine maturation.
𝛼-Fodrin which interacts with the ankyrin repeats of
Shank via its spectrin motif can bind with F actin [78]. Fur-
ther, ProSAPiP1 (ProSAP interacting protein), an interaction
partner of the Shank3 PDZ domain, has an actin binding
domain and thus it can influence actin remodeling [79]. In
addition, the Abp1 (actin binding protein 1) is an interaction
partner of Shank, which interacts with the SH3 domain [80].
Abp1 can regulate actin remodeling in the spine head and thus
participates in spine morphogenesis [80]. Finally, besides
Homer1 and cortactin, Abi-1 (Abelson interacting protein
1) interacts with the proline-rich region of Shank3. Abi-1
can modulate spine morphology and synapse formation [81]
(Figure 5(a)).
Shank proteins also interact with SPIN90 (SH3 protein
interacting with Nck, 90 kDa), which plays an important role
in actin polymerization, endocytosis, growth cone formation,
and dendritic spinemorphogenesis [82]. SPIN90 is phospho-
rylated by Src kinase [83], which leads, similar to overex-
pression of SPIN90, to enlargement of spines, while SPIN90
knock-out in neurons results in an altered actin cytoskeleton
[83]. Further, neural Abelson-related gene-binding protein 2
(nArgBP2), a protein that interacts with SAPAP3 and Shank3,
was found to regulate spine morphogenesis through the
activation of the Rac1/WAVE/PAK/cofilin pathway [84].
Taken together, these interactions provide a strong link
between Shank proteins and actin regulating signaling path-
ways. Within the PSD, Shank3 is concentrated preferentially
in the distal layer after synaptic activity and in presence of
Zn2+ [43]. It has been hypothesized that subsequent recruit-
ment of Shank binding proteins such as IRSp53, Abp1, and
cortactin to the distal layer could mediate acute regulation of
the actin cytoskeleton in response to synaptic activity [85].
Thus, mechanistically, Shank proteins might be in the center
of a PSD actinmodulatory complex, regulating synaptic actin
dynamics via several central pathways.
3.3. Shank Signaling Affecting Small GTPases. Some interac-
tion partners of Shank proteins act as modulators for small
GTPases. One such interaction partner of Shank3 is RICH2
(RhoGAP interacting with CIP4 homolog 2). The RICH2
protein interacts with the PDZ domain of Shank3 via its
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Figure 5: Cross talk between Shank and small GTPases. (a) The domain architecture of Shank proteins and their interaction partners. The
Shank protein consists of 5 different important domains: N-terminal ankyrin repeats, Src homology domain 3 (SH3), PSD-95/Dlg/ZO-1
domain (PDZ domain), proline-rich region, and C-terminal sterile alpha motive. Different proteins can interact with different domains. For
example, the C-terminus of GKAP, small GTPase modulator 𝛽PIX, ProSAP interacting protein (ProSAPiP), and the C-terminal STAV motif
of RICH2 can interact with the PDZ domain of Shank3. Between the PDZ domain and SAMdomain, there is a gap of more that 1000 residues,
which is proline-rich.This proline-rich region can interact withHomer, IRSp53, Abi-1, and cortactin.The SAMdomain of Shank2 and Shank3
can bind with other SAM domains upon zinc sequestration organizing platforms in an antiparallel manner. (b) Within the dendritic spine,
Shanks interact with a wide range of proteins, for example, linking other scaffoldingmolecules like PSD-95, Homer, andGKAP and associated
receptors to the actin cytoskeleton. Some of Shank’s interaction partners are modulators of small GTPases; thereby they can activate actin
remodeling via GTPase signaling. The interaction partners cortactin and 𝛼-fodrin can stabilize actin. Such actin reorganization alters the
morphology and maturity of spines and strengthens synaptic transmission.
C-terminal STAL/STAV motif. In vitro studies show that,
during LTP, the Shank3-RICH2 interaction is increased and
localized at the dendritic spine. Additionally, RICH2 controls
AMPA receptor trafficking and spine morphology [86]. As
RICH, the firstly identified homolog of RICH2, RICH2 was
identified as a GAP protein for Rac1 and Cdc42 [87]. In
the RICH2 knock-out mouse model, the brain size was
increased, synaptic NMDA receptor levels were increased,
and the spine area was enlarged. Further, a high number of
fused multiple spine synapses were detected [66]. Moreover,
in this mouse model, Rac1 and Cdc42 were identified as
the candidate small GTPases on which RICH2 can exert its
RhoGAP activity. Deletion of RICH2 leads to constitutive
active signaling of Rac1 and Cdc42, which mediate actin
polymerization. Interestingly, this mouse model showed a
subset of autistic symptoms on behavioral level such as
an increase in stereotypic movements. Additionally, RICH2
knock-outmice had a specific fear of novelty in terms of novel
objects.
𝛽PIX, a RhoGEF for Rac1 and Cdc42, can interact with
the PDZ domain of Shank using its leucine zipper domain
and PDZ binding domain [88]. Shank can bind with 𝛽PIX
and 𝛽PIX associated signaling molecules like PAK (p21-
associated kinase). Since PAK is a downstream signaling
molecule of Rac1 and Cdc42, such interaction can affect
small GTPase signaling and actin remodeling [51]. Deletion
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of 𝛽PIX in drosophila leads to neuromuscular junction
defects and reduction of synaptic proteins including PAK and
glutamate receptor [89].
IRSp53 (insulin receptor tyrosine substrate kinase 3)
interacts with the proline-rich region of Shank3. IRSp53 is
an insulin receptor substrate in the brain and acts in the
downstream signaling of the small GTPase Cdc42. In this
way, IRSp53 modulates the organization of spines and actin
[90]. Besides Shank3, IRSp53 can also interact with PSD-95
and recruit PSD-95 to the spines [91]. Thus, IRSp53 can form
a tripartite complex with Shank and PSD-95, linking again
the spine morphogenesis and small GTPase signaling.
Some modulators of the small GTPases are also indirect
interaction partners of Shank proteins. One such modulator
is SPAR. SPAR can interact with the PDZ domain of Shank
using ProSAPiP1 as linkermolecule [92]. It was first identified
in a yeast two-hybrid screen using the guanylate kinase (GK)
domain of the PSD-95 family member PSD-93 [93, 94]. SPAR
acts as a GAP protein for Rap small GTPases. SPAR has
two actin interacting domains and it colocalizes with PSD-
95 in dendritic spines of hippocampal neurons in culture.
Overexpression of SPAR leads tomultilobed shaped dendritic
spines. Moreover, SPAR can reorganize F actin into large
aggregates [93].
Thus, there is significant overlap between the Shank
mediated action on dendritic morphology and small GTPase
mediated signaling pathways targeting actin dynamics. It is
thus possible that Shank signaling at synapses intersects with
these pathways, which drive the formation, maturation, and
activation of dendritic spines (Figure 5(b)).The receptors that
are mainly responsible for synaptic plasticity-driven spine
remodeling are NMDA receptors. Shank proteins act as a
scaffold, holding other scaffolding molecules like Homer1,
GKAP, and PSD-95, thus facilitating the recruitment of
NMDA receptors. NMDA receptors in turn can regulate
small GTPase modulators like Kalirin-7 using various mech-
anisms like phosphorylation and calcium dependent kinases.
4. Shank and Small GTPase Modulators in
Neurological Disorders
ASD are identified as a term collectively describing various
similar neurological disorders. The core features of ASD
are language and communication impairment, deficits in
social interaction, and repetitive stereotypic behaviors [95].
In addition to these, there are many other psychological
disturbances like anxiety, sleep disturbances, and epilepsy,
as well as comorbidities such as gastrointestinal abnormal-
ities. ASD are considered as heritable disorders often with
environmental factors acting on a specific genetic back-
ground to trigger the disease, and till now more than 100
genes have been associated with ASD [96, 97]. The range
of synaptic proteins that has been associated with ASD
is quite diverse. They include NMDA receptors (GRIN2A,
GRIN2B, and GABRB3), master PSD scaffolding proteins
(SHANK2, SHANK3, and glutamate receptor interacting
protein 1), PSD adhesion molecules (Contactin 4, Contactin
associated protein like-2/4, neurexin 1, neuroligin 3, and
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Figure 6:ASDassociated pathways. In very few cases, ASD is caused
by the dysfunction of a single gene, for example, in syndromic
forms of autism such as Rett syndrome (mutation in MeCP2
gene), Angelman syndrome (UBE3A gene), and fragile X syndrome
(FMRP1 gene). In nonsyndromic forms, mutations in PSD adhesion
molecules like neurexin and neuroligin and structural proteins like
Shank are frequently found at excitatory synapses. This may lead
to mGluR5 or NMDA receptor dysregulation (i.e., GRIN2A/B)
and ultimately, among others, calcium homeostasis imbalance,
disruption in signaling pathways like Wnt or mTOR signaling,
and dysfunction of nuclear signaling. Underlying or accompanying
all these alterations are impairments in action dynamics within
dendritic spines.
neuroligin 4), and hormonal receptors (oxytocin receptor)
[97]. It has been hypothesized that mutation in synapse
associated proteins producesmutated/truncated proteins that
are unable to perform their normal physiological functions,
which ultimately leads to circuit dysfunction and finally
behavior abnormalities [97]. Surprisingly, many of these ASD
candidate genes intersect at common pathways at synapses
(Figure 6). Such pathways, for example, control synapse
formation and receptor trafficking. Actin remodeling is a
major contributor to these processes.
Given the central role of SHANK in disorders such as
ASD, it is likely that impairment in these processes is a major
contributor to the phenotypes observed after mutation or
deletion of SHANK genes. Recently several modulators of
GTPase have been found to be associated with neurological
disorders, due to the profound effect of small GTPases on
dendritic spine morphogenesis. Most common of these is
intellectual disability.Mutation in oligopherinin 1, a RhoGAP
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Table 1: Rho GTPase modulators in mental disorders.
Protein Gene GTPase signaling Clinical features Effect of mutation onspine morphogenesis Interaction with Shank
Oligophrenin 1 OPHN1 GAP forRac1/Cdc42/RhoA
Intellectual disability,
microcephaly, ataxia,
hypersensitivity
↓ on spine length and
maturation Indirect via Homer
MEGAP MEGAP GAP for Rac1/Cdc42 Microcephaly, facialdisfigurement
Loss of filopodia and
lamellipodia Not known
RICH2 ARHGAP44 GAP for Rac1/Cdc42 No mutation yet identifiedin human
↑ spine area, multiple
spines fused together Direct
𝛼PIX ARHGEF6 GEF for Rac1/Cdc42 Intellectual disability ↓ spine with mushroommorphology Not known
𝛽PIX ARHGEF7 GEF for Rac1/Cdc42 No mutation yet identifiedin human
↓ synaptic proteins,
defective NMJ Direct
Alsin ALS2 GEF for Rac1, Rab5,Ran Motor neuron degeneration
↓ axon growth, ↑ cell
death Not known
for RhoA, Rac1, and Cdc42, leads to reduction in spine length
and number of mature spines accompanied by resulting
phenotypes including intellectual disability, epilepsy, micro-
cephaly, ataxia, and hyperactivity [98, 99].
Dysregulation of MEGAP, another RhoGAP for Rac1 and
Cdc42, has also been associated with intellectual disability
and microcephaly. Additionally, the individuals have long
faces and long ears [100]. MEGAP interacts with Homer,
which is a direct interaction partner of Shank [101]. Two
GEF modulators, ARHGEF6 (or 𝛼PIX) and Alsin, have been
identified as the causative genes for intellectual disability
and motor neuron degeneration [102–106]. Mutation in
Alsin, a GEF for Rac1, Rab5, and Ran, leads to increased
neuronal death and reduced axon growth, whereas mutation
in ARHGEF6, a GEF for Rac and Cdc42, decreases the
amount of mature mushroom type spines [107].
Besides modulators, some effector molecules have been
identified as causative genes for intellectual disability. Exam-
ples include PAK3, LIMK1, and FMRP (interacting with the
downstream effector of Rac1, CYFIP). Mutation in PAK3
alters synaptic efficacy via impairing LTP and decreasing
mature synapses [108]. FMRP (fragile X mental retardation
protein) is most commonly associated with fragile X syn-
drome. It is also an indirect downstream effector of Rac1
[109, 110]. Further, the Rap1 GEF, Epac2, has been associated
with ASD [111–113]. Mutations in SynGAP1, a Ras GAP, have
been found in a patient suffering from ASD and intellectual
disability [114–117]. Intriguingly, mutations in SHANK3 are
highly associatedwith intellectual disability and are especially
abundant in patients suffering from ASD with moderate to
profound intellectual disability [118].
Taken together, different mutations in small GTPase
effectors and modulators have been associated with mental
abnormalities (Table 1). Small GTPase modulators and effec-
tors are able to create phenotypic alteration in human via
modifying spine morphology [107] which were also observed
in SHANK knock-out mouse models.
5. Abnormal Actin Remodeling
in Shankopathies
Identification of Shank3 mutation (22q13.3 deletion, Phelan
McDermid syndrome) in a patient was the first link of Shank
proteins with neuropsychiatric disorders in humans [119,
120]. SHANK3 is one of the best characterized genes associ-
ated with ASD. Shank mutations may lead to other comor-
bidities, besides ASD, like intellectual disability, schizophre-
nia, bipolar disorder, and attention deficit and hyperactivity
disorder (ADHD) [4, 5]. Shank3 duplication can lead to other
symptoms like ADHD and bipolar disorder in human [73].
Shank mutations have been identified in almost 1% of all
ASD patients [118]. The mutations vary a lot in terms of
the peptide residues including whole exon deletion, whole
domain deletion, and even point mutations. Mutations in
Shank have very high penetrance at the phenotypic level, and
any form of Shank3 haploinsufficiency is enough to cause
behavioral disturbances [5].
Golgi analyses in the postmortemASDbrain tissues show
that there are alterations in dendritic spine density [121, 122].
Since the Shank proteins are modulators of dendritic spine
morphogenesis, it is very possible that mutation or deletion
of Shank leads to alteration in spine homeostasis.
Many mouse and rat models have been generated across
the globe to mimic human Shankopathies. For example,
several groups studied Shank1 knock-outmice [123–125].This
mouse model had alteration in synaptic protein composition
but also impairments in dendritic spine morphology; the
number of dendritic spines was reduced, and the spines were
thinner and smaller.
Shank2 knock-out mice that exhibit almost all the core
features of ASD like increased stereotypic behavior, impair-
ment in social interaction, hyperactivity, and anxiety [126]
similarly show a reduction in the number of dendritic spines
and basal synaptic transmission with depletion of NMDA
receptors [126]. Allosteric mGluR5 modulators, partial ago-
nists of NMDARs (D-cycloserine), and the zinc ionophore
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clioquinol rescued the phenotype by enhancedNMDArecep-
tor activity [127, 128].
Several mouse models have been generated to investigate
the role of Shank3 and its splice variants in ASD. Recently,
complete knock-out of Shank3 in mice was published [129].
In Shank3𝛼 and Shank3𝛽 knock-out mice, the corticostriatal
circuitry is defective and fewer and thinner PSDs were
detected; in addition, the amount of receptors and scaffolding
proteins was reduced. In the complete Shank3 knock-out
mouse model, mGluR5-Homer scaffolds and mGluR5 sig-
naling are impaired. Additionally, the autistic mouse model
showed impaired function of striatal synapses and abnormal-
ities in brain morphology [129].
Further, Shank3 knock-out mice were reported to suffer
from a loss of cortical actin filaments. A reduced Rac1/PAK
activity along with increased activity of cofilin, the major
actin depolymerizing factor, has been identified as the under-
lying biological process for this phenotype. The aberrant
regulation of synaptic actin filaments thatmight be connected
to the loss of synaptic NMDAR observed in these animals
was proposed to contribute to their autism-like behavior.
Intriguingly, the social deficits and NMDAR hypofunction
were rescued by inhibition of cofilin or activation of Rac1
signaling [130].
Thus, Shank proteins and their various interaction part-
ners are able to modulate spine morphogenesis via actin
remodeling in response to synaptic activity (Figure 7). Upon
synaptic activation, zinc is released from the presynaptic
terminal at zincergic synapses. The free zinc can bind to
receptors such as NMDAR on the postsynapse or enter the
postsynaptic terminal. Additionally, at zincergic but also
other neurons, zinc levels may increase within the postsy-
napse by release from intracellular stores likemetallothionein
3 upon neuronal activation, which triggers the recruitment
of Shank2 and Shank3 proteins to the PSD via formation
of Shank platforms providing the framework for binding
of other proteins. That way, further direct and indirect
interacting partners can bind to the scaffold andmodulate the
PSD and spine using different mechanisms [131].
To start from the N terminal, the less well known SPN
domain (Shank/ProSAP N-terminal domain) has a role in
the function of the ankyrin repeat domain (ANK). Recently
it has been shown that the SPN domain is able to interact
with the ANK domain of the same protein, thus creating
an intramolecular interaction [132] and thereby reducing the
accessibility of the ANK domain. Through this, interaction
partners of ANK domain like 𝛼-fodrin and sharpin are
unable to bind with Shank3. Some point mutations have
been identified in the SPN domain of Shank3. Due to these
mutations, the SPN domain loses its ability to bind with
the ANK domain, thereby enhancing sharpin and 𝛼-fodrin
recruitment [132].
The cytoskeletal protein 𝛼-fodrin interacts with the ANK
domains of both Shank1 and Shank3 using its conserved
spectrin motif [78]. Fodrin can bind with actin and stabilizes
actin filament. Additionally, fodrin serves as a calmodulin
binding protein [133]. Therefore, indirectly fodrin can link
Shank proteins with the calcium sensing mechanism in the
neuron. Besides 𝛼-fodrin, the C terminal of sharpin can
also bind with the ANK domain of Shank proteins [134].
Different point mutations in the ANK domain have been
identified that lead to a decrease in actin filaments [135]
as well as spine density and spine maturation. In case the
ANK domain is deleted or mutated, 𝛼-fodrin and sharpin
are unable to bind Shank. This, on one hand, affects actin
stabilization via 𝛼-fodrin and, on other hand, hampers the
sharpin-Shank scaffolding. For Shank3, many mouse models
have been generated to investigate its role in PSD. This list
today includes at least 5 different partial knock-out mouse
models, one complete knock-out model, and an overexpres-
sion mouse model [73, 126, 129, 136–139]. Twomouse models
harbor deletion of exons 4–9 in the ANK domain [136, 138].
Since the ANK domain binds with sharpin and 𝛼-fodrin,
impairment of these interactionmight be an underlying cause
for the alterations observed in the PSD protein composition
[138]. The spine length was increased without any increase in
spine head and the total number of spines was reduced.
The PDZ domain of Shank is very important in terms
of its scaffolding function. Several small GTPase modulators
(i.e., RICH2 and 𝛽PIX) and other scaffolding proteins (i.e.,
GKAP) bind at this domain. RICH2 acts as a RhoGAP for
Rac1 and Cdc42. If RICH2 is activated, it inactivates Rac1 and
Cdc42. Rac1 and Cdc42 enhance dendritic morphogenesis.
Thus, activation of RICH2 is associated with spine size
reduction. On the other hand, if RICH2 is deleted, both Rac1
and Cdc42 are hyperactivated leading to changes in spine
shape and morphology [66]. The function of Shank3 bound
Rich2 and Shank3 unbound Rich2 is opposite in in vitro
models [86]. Upon cLTP,mutated Rich2 that is unable to bind
with Shank3 inhibits spine head enlargement. This points to
a role of Shank3 as inactivator of Rich2 to promote spine
enlargement.
Another small GTPase regulator that binds with the
PDZ domain of Shanks is 𝛽PIX [88]. 𝛽PIX works as a
RhoGEF for Rac1 and Cdc42. If 𝛽PIX is activated, it converts
the GDP bound inactive Rac1/Cdc42 to GTP bound active
Rac1/Cdc42 activating the downstream signaling molecules.
Unlike Rich2, if 𝛽PIX interacts with Shank3, it is acti-
vated, which promotes spine enlargement. Thus, binding of
both 𝛽PIX and Rich2 may increase the activation state of
Rac1/Cdc42 in the dendritic spine due to the different effects
of Shank3 on the activity of these proteins [66, 88].
Pec¸a et al. characterized a mouse model which had
deletion in exons 13–16, spanning the PDZ domain of Shank3
[139]. A number of PSD proteins and receptors were reduced
in this mouse model. In the striatum, several morpholog-
ical abnormalities of dendritic spines were observed like
a decrease in spine density, length, and thickness. All this
points to the fact that the PDZ domain is important for the
scaffolding function of Shank3 and for the maintenance of
spine structure and function.
The proline-rich domain of Shank3 proteins is also very
important for synaptic signaling as it binds cortactin, Abi-
1, and IRSp53. Cortactin binds and stabilizes F actin. Abi-1
is in a complex with proteins such as WASP/WAVE, EPS8,
and cortactin, thereby regulating the actin cytoskeleton via
the Arp2/3 complex [81]. Knock-down of Abi-1 reduces
synapse density, while it increases dendritic branching and
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Figure 7: Shank3 and its interaction partners can affect actin cytoskeleton and spine morphology via various pathways. Shank3 and its many
interaction partners can affect spine maturation and morphogenesis. Ankyrin repeat domain interaction partners, sharpin and 𝛼-fodrin,
enable spine enhancement via Shank scaffold stabilization and F actin stabilization. SH3 domain interaction partner, Abp1, enhances F
actin formation. Other scaffolding molecules, GKAP and Homer, can interact with Shank3 and take part in AMPA, NMDA, and mGluR
modulation. Small GTPase modulator like 𝛽PIX activates Rac1 and/or Cdc42 and enables F actin formation and spine morphogenesis.
Cortactin, intertion partner of proline-rich domain, binds and stabilizes F actin.Thus, most of the Shank3 interaction partners have a positive
role in spinemorphogenesis andmutations or deletions result in spine shrinkage and loss of synapses. An exception is Rich2. Rich2 deactivates
Rac1 and/or Cdc42 and thus can take part in spine size reduction and spine loss. Shank3 bound Rich2 is inactive.Therefore, a switch between
Shank3/Rich2 to Shank3 and unbound Rich2 at the PSD may be an important integrator of the translation of synaptic activity in controlled
and restricted spine growth. It is mentionworthy that, at any certain time point, only one interaction partner of the same domain can bind
with Shank3.
the number of immature spines. Like Rich2 and𝛽PIX, IRSp53
links small GTP signaling pathways and Shank signaling, as
it acts as a downstream effector of Cdc42. Therefore, this
domain, along with its interaction partners, promotes spine
enlargement and maturation.
Recently a complete knock-out mouse model of Shank3
has been characterized which has deletion of exons 4–22
in Shank3 [129]. There were reductions in spine density and
spine length (in striatum). A Shank3 overexpression mouse
model overexpressing themajor isoforms of Shank3 confirms
that Shank3 can directly interact with Arp2/3 andmany other
actin modulators and small GTPase signaling proteins [73].
However, the actual interplay among these proteins is yet to
be determined.
Neural Plasticity 11
From these data, a model can be hypothesized, according
to which synaptic activity should facilitate an open con-
formation of Shank3 regarding its SPN and ANK domains
to enable binding of proteins promoting F actin formation
and subsequent stabilization. Further, proteins such as 𝛽PIX
should induce the activation of modulators of small GTPases
such as Rac1 and Cdc42 that lead to enlargement of spines
mediated by proteins that in part are found in a complex with
theC-terminal domains of Shank3.Alternatively, recruitment
of specific Shank3 isoformswith specific domain composition
enabling the binding of these factors may occur. In addition,
Shank3 recruiting Rich2 to its PDZ domain will facilitate
spine enlargement due to an inhibitory effect on the RhoGAP
activity of Rich2 (Figure 7).
6. Conclusions
The different isoforms of Shank proteins and their interac-
tion partners have a pivotal role in synaptic plasticity via
actin remodeling. Because of the different protein-protein
interaction domains, Shank can directly and indirectly affect
actin dynamics, for example, via small GTPases. This points
towards a central physiological role of the synaptic Shank
complex in translating synaptic activity in structural and
associated changes. Given that actin remodeling is a central
motif of Shank signaling, it may not be surprising that
the pathomechanisms of ASD associated mutation in Shank
proteins also converge on this process. Since the study on
small GTPases is much older than the study on Shank,
knowledge acquired by small GTPase studies can be at least
to some extent useful for the field of Shankopathies.
Abbreviations
ASD: Autism spectrum disorders
ProSAP: Proline-rich synapse
associated protein
PSD: Postsynaptic density
Shank: SH3 domain and ankyrin
repeat containing protein
AMPA: 𝛼-Amino-3-hydroxy-5-
methyl-4-isoxazolepropionic
acid
NMDA: N-Methyl-D-aspartate
LTP: Long-term potentiation
LTD: Long-term depression
mEPSC: miniature excitatory
postsynaptic currents.
Competing Interests
The authors declare no competing financial interests.
Acknowledgments
Andreas M. Grabrucker is supported by the Else-Kro¨ner-
Fresenius Stiftung (214 A251) and the Juniorprofessuren-
Programm of the state of Baden-Wu¨rttemberg. Tasnuva
Sarowar is supported under the Postgraduate Scholarships
Act of the Land of Baden-Wuerttemberg (LGFG).
References
[1] L. A. Cingolani and Y. Goda, “Actin in action: the interplay
between the actin cytoskeleton and synaptic efficacy,” Nature
Reviews Neuroscience, vol. 9, no. 5, pp. 344–356, 2008.
[2] T. Bourgeron, “From the genetic architecture to synaptic plastic-
ity in autism spectrum disorder,” Nature Reviews Neuroscience,
vol. 16, no. 9, pp. 551–563, 2015.
[3] C.Heise, J. C. Schroeder,M. Schoen et al., “Selective localization
of shanks to VGLUT1-positive excitatory synapses in themouse
hippocampus,” Frontiers in Cellular Neuroscience, vol. 10, article
106, 2016.
[4] A. Guilmatre, G. Huguet, R. Delorme, and T. Bourgeron, “The
emerging role of SHANK genes in neuropsychiatric disorders,”
Developmental Neurobiology, vol. 74, no. 2, pp. 113–122, 2014.
[5] Y.-H. Jiang andM.D. Ehlers, “Modeling autismby SHANKgene
mutations in mice,” Neuron, vol. 78, no. 1, pp. 8–27, 2013.
[6] E. N. Firat-Karalar and M. D. Welch, “New mechanisms and
functions of actin nucleation,” Current Opinion in Cell Biology,
vol. 23, no. 1, pp. 4–13, 2011.
[7] S. Shekhar, J. Pernier, and M. Carlier, “Regulators of actin
filament barbed ends at a glance,” Journal of Cell Science, vol.
129, no. 6, pp. 1085–1091, 2016.
[8] C. G. Dos Remedios, D. Chhabra, M. Kekic et al., “Actin
binding proteins: regulation of cytoskeletal microfilaments,”
Physiological Reviews, vol. 83, no. 2, pp. 433–473, 2003.
[9] T. D. Pollard and G. G. Borisy, “Cellular motility driven by
assembly and disassembly of actin filaments,” Cell, vol. 112, no.
4, pp. 453–465, 2003.
[10] C. Revenu, R. Athman, S. Robine, and D. Louvard, “The co-
workers of actin filaments: from cell structures to signals,”
Nature ReviewsMolecular Cell Biology, vol. 5, no. 8, pp. 635–646,
2004.
[11] J. A. Cooper, “Effects of cytochalasin and phalloidin on actin,”
The Journal of Cell Biology, vol. 105, no. 4, pp. 1473–1478, 1987.
[12] T. C. Su¨dhof, “The synaptic vesicle cycle,” Annual Review of
Neuroscience, vol. 27, pp. 509–547, 2004.
[13] D.Drenckhahn,M. Frotscher, andH.W.Kaiser, “Concentration
of F-actin in synaptic formations of the hippocampus as visu-
alized by staining with fluorescent phalloidin,” Brain Research,
vol. 300, no. 2, pp. 381–384, 1984.
[14] D. Drenckhahn and H. Kaiser, “Evidence for the concentration
of F-actin and myosin in synapses and in the plasmalemmal
zone of axons,” European Journal of Cell Biology, vol. 31, no. 2,
pp. 235–240, 1983.
[15] F. Capani, M. E. Martone, T. J. Deerinck, and M. H. Ellisman,
“Selective localization of high concentrations of F-actin in sub-
populations of dendritic spines in rat central nervous system:
a three-dimensional electron microscopic study,” Journal of
Comparative Neurology, vol. 435, no. 2, pp. 156–170, 2001.
[16] O. Bloom, E. Evergren, N. Tomilin et al., “Colocalization
of synapsin and actin during synaptic vesicle recycling,” The
Journal of Cell Biology, vol. 161, no. 4, pp. 737–747, 2003.
[17] P. Chi, P. Greengard, and T. A. Ryan, “Synapsin dispersion and
reclustering during synaptic activity,” Nature Neuroscience, vol.
4, no. 12, pp. 1187–1193, 2001.
[18] P. Chi, P. Greengard, and T. A. Ryan, “Synaptic vesicle mobi-
lization is regulated by distinct synapsin I phosphorylation
12 Neural Plasticity
pathways at different frequencies,”Neuron, vol. 38, no. 1, pp. 69–
78, 2003.
[19] G. R. Phillips, J. K. Huang, Y. Wang et al., “The presynap-
tic particle web: ultrastructure, composition, dissolution, and
reconstitution,” Neuron, vol. 32, no. 1, pp. 63–77, 2001.
[20] J. E. Heuser and T. S. Reese, “Evidence for recycling of
synaptic vesiclemembrane during transmitter release at the frog
neuromuscular junction,”The Journal of Cell Biology, vol. 57, no.
2, pp. 315–344, 1973.
[21] M. H. Arons, C. J. Thynne, A. M. Grabrucker et al., “Autism-
associated mutations in ProSAP2/Shank3 impair synaptic
transmission and neurexin-neuroligin-mediated transsynaptic
signaling,” The Journal of Neuroscience, vol. 32, no. 43, pp.
14966–14978, 2012.
[22] G. Meyer, F. Varoqueaux, A. Neeb, M. Oschlies, and N. Brose,
“The complexity of PDZ domain-mediated interactions at
glutamatergic synapses: a case study on neuroligin,”Neurophar-
macology, vol. 47, no. 5, pp. 724–733, 2004.
[23] A. M. Craig and Y. Kang, “Neurexin-neuroligin signaling in
synapse development,” Current Opinion in Neurobiology, vol. 17,
no. 1, pp. 43–52, 2007.
[24] C. Dean, F. G. Scholl, J. Choih et al., “Neurexin mediates the
assembly of presynaptic terminals,” Nature Neuroscience, vol. 6,
no. 7, pp. 708–716, 2003.
[25] C. I. Nam and L. Chen, “Postsynaptic assembly induced by
neurexin-neuroligin interaction and neurotransmitter,” Pro-
ceedings of the National Academy of Sciences of the United States
of America, vol. 102, no. 17, pp. 6137–6142, 2005.
[26] S. Halbedl, M. Schoen, M. S. Feiler, T. M. Boeckers, and M. J.
Schmeisser, “Shank3 is localized in axons and presynaptic spe-
cializations of developing hippocampal neurons and involved
in the modulation of NMDA receptor levels at axon terminals,”
Journal of Neurochemistry, vol. 137, no. 1, pp. 26–32, 2016.
[27] T. Kuriu, A. Inoue, H. Bito, K. Sobue, and S. Okabe, “Differential
control of postsynaptic density scaffolds via actin-dependent
and-independent mechanisms,” The Journal of Neuroscience,
vol. 26, no. 29, pp. 7693–7706, 2006.
[28] D. W. Allison, V. I. Gelfand, I. Spector, and A. M. Craig,
“Role of actin in anchoring postsynaptic receptors in cultured
hippocampal neurons: differential attachment of NMDA versus
AMPA receptors,”The Journal of Neuroscience, vol. 18, no. 7, pp.
2423–2436, 1998.
[29] J. Kirsch and H. Betz, “The postsynaptic localization of the
glycine receptor-associated protein gephyrin is regulated by the
cytoskeleton,” The Journal of Neuroscience, vol. 15, no. 6, pp.
4148–4156, 1995.
[30] N. Honkura, M. Matsuzaki, J. Noguchi, G. C. R. Ellis-Davies,
and H. Kasai, “The subspine organization of actin fibers regu-
lates the structure and plasticity of dendritic spines,” Neuron,
vol. 57, no. 5, pp. 719–729, 2008.
[31] Q. Zhou, M.-Y. Xiao, and R. A. Nicoll, “Contribution of
cytoskeleton to the internalization of AMPA receptors,” Pro-
ceedings of the National Academy of Sciences of the United States
of America, vol. 98, no. 3, pp. 1261–1266, 2001.
[32] K. E. Sorra and K. M. Harris, “Overview on the structure, com-
position, function, development, and plasticity of hippocampal
dendritic spines,”Hippocampus, vol. 10, no. 5, pp. 501–511, 2000.
[33] E. N. Star, D. J. Kwiatkowski, and V. N.Murthy, “Rapid turnover
of actin in dendritic spines and its regulation by activity,”Nature
Neuroscience, vol. 5, no. 3, pp. 239–246, 2002.
[34] I. Hlushchenko, M. Koskinen, and P. Hotulainen, “Dendritic
spine actin dynamics in neuronal maturation and synaptic
plasticity,” Cytoskeleton, vol. 73, no. 9, pp. 435–441, 2016.
[35] K.-I. Okamoto, T. Nagai, A. Miyawaki, and Y. Hayashi, “Rapid
and persistent modulation of actin dynamics regulates post-
synaptic reorganization underlying bidirectional plasticity,”
Nature Neuroscience, vol. 7, no. 10, pp. 1104–1112, 2004.
[36] Y. Fukazawa, Y. Saitoh, F. Ozawa, Y. Ohta, K. Mizuno, and K.
Inokuchi, “Hippocampal LTP is accompanied by enhanced F-
actin content within the dendritic spine that is essential for late
LTP maintenance in vivo,” Neuron, vol. 38, no. 3, pp. 447–460,
2003.
[37] Y. Takumi, V. Ramı´rez-Leo´n, P. Laake, E. Rinvik, and O. P.
Ottersen, “Different modes of expression of AMPA and NMDA
receptors in hippocampal synapses,” Nature Neuroscience, vol.
2, no. 7, pp. 618–624, 1999.
[38] T. M. Boeckers, J. Bockmann, M. R. Kreutz, and E. D.
Gundelfinger, “ProSAP/Shank proteins—A family of higher
order organizing molecules of the postsynaptic density with
an emerging role in human neurological disease,” Journal of
Neurochemistry, vol. 81, no. 5, pp. 903–910, 2002.
[39] S. Naisbitt, K. Eunjoon, J. C. Tu et al., “Shank, a novel family
of postsynaptic density proteins that binds to the NMDA
receptor/PSD-95/GKAP complex and cortactin,” Neuron, vol.
23, no. 3, pp. 569–582, 1999.
[40] A. M. Grabrucker, “A role for synaptic zinc in ProSAP/Shank
PSD scaffold malformation in autism spectrum disorders,”
Developmental Neurobiology, vol. 74, no. 2, pp. 136–146, 2014.
[41] A. M. Grabrucker, M. J. Knight, C. Proepper et al., “Con-
certed action of zinc and ProSAP/Shank in synaptogenesis and
synapse maturation,”TheEMBO Journal, vol. 30, no. 3, pp. 569–
581, 2011.
[42] S. Grabrucker, L. Jannetti, M. Eckert et al., “Zinc deficiency
dysregulates the synaptic ProSAP/Shank scaffold and might
contribute to autism spectrum disorders,” Brain, vol. 137, no. 1,
pp. 137–152, 2014.
[43] J.-H. Tao-Cheng, D. Toy, C. A. Winters, T. S. Reese, and A.
Dosemeci, “Zinc stabilizes Shank3 at the postsynaptic density
of hippocampal synapses,” PloS ONE, vol. 11, no. 5, Article ID
e0153979, 2016.
[44] M. Sheng and E. Kim, “The Shank family of scaffold proteins,”
Journal of Cell Science, vol. 113, no. 11, pp. 1851–1856, 2000.
[45] S. Lim, S. Naisbitt, J. Yoon et al., “Characterization of the
Shank family of synaptic proteins. Multiple genes, alternative
splicing, and differential expression in brain and development,”
The Journal of Biological Chemistry, vol. 274, no. 41, pp. 29510–
29518, 1999.
[46] H. Zitzer, H.-H. Ho¨nck, D. Ba¨chner, D. Richter, and H.-J.
Kreienkamp, “Somatostatin receptor interacting protein defines
a novel family of multidomain proteins present in human and
rodent brain,” The Journal of Biological Chemistry, vol. 274, no.
46, pp. 32997–33001, 1999.
[47] T. M. Boeckers, M. R. Kreutz, C. Winter et al., “Proline-
rich synapse-associated protein-1/cortactin binding protein 1
(ProSAP1/CortBP1) is a PDZ-domain protein highly enriched
in the postsynaptic density,”The Journal of Neuroscience, vol. 19,
no. 15, pp. 6506–6518, 1999.
[48] M. D. Ehlers, “Synapse structure: glutamate receptors con-
nected by the shanks,” Current Biology, vol. 9, no. 22, pp. R848–
R850, 1999.
Neural Plasticity 13
[49] M. Sheng and C. Sala, “PDZ domains and the organization
of supramolecular complexes,” Annual Review of Neuroscience,
vol. 24, no. 1, pp. 1–29, 2001.
[50] C. Sala, V. Pie¨ch, N. R. Wilson, M. Passafaro, G. Liu, and M.
Sheng, “Regulation of dendritic spinemorphology and synaptic
function by Shank and Homer,” Neuron, vol. 31, no. 1, pp. 115–
130, 2001.
[51] K. M.Woolfrey and D. P. Srivastava, “Control of dendritic spine
morphological and functional plasticity by small GTPases,”
Neural Plasticity, vol. 2016, Article ID 3025948, 12 pages, 2016.
[52] T. Bonhoeffer and R. Yuste, “Spine motility: phenomenology,
mechanisms, and function,”Neuron, vol. 35, no. 6, pp. 1019–1027,
2002.
[53] A. Tashiro and R. Yuste, “Regulation of dendritic spine motility
and stability by Rac1 and Rho kinase: evidence for two forms of
spine motility,”Molecular and Cellular Neuroscience, vol. 26, no.
3, pp. 429–440, 2004.
[54] C. F. Bento, C. Puri, K. Moreau, and D. C. Rubinsztein, “The
role ofmembrane-trafficking small GTPases in the regulation of
autophagy,”The Journal of Cell Science, vol. 126, no. 5, pp. 1059–
1069, 2013.
[55] A. Tashiro, A. Minden, and R. Yuste, “Regulation of dendritic
spine morphology by the Rho family of small GTPases: antago-
nistic roles of Rac and Rho,” Cerebral Cortex, vol. 10, no. 10, pp.
927–938, 2000.
[56] H. Zhang, D. J. Webb, H. Asmussen, S. Niu, and A. F. Horwitz,
“A GIT1/PIX/Rac/PAK signaling module regulates spine mor-
phogenesis and synapse formation through MLC,” The Journal
of Neuroscience, vol. 25, no. 13, pp. 3379–3388, 2005.
[57] Y. Meng, Y. Zhang, V. Tregoubov et al., “Abnormal spine
morphology and enhanced LTP in LIMK-1 knockout mice,”
Neuron, vol. 35, no. 1, pp. 121–133, 2002.
[58] M. Maekawa, T. Ishizaki, S. Boku et al., “Signaling from Rho to
the actin cytoskeleton through protein kinases ROCK and LIM-
kinase,” Science, vol. 285, no. 5429, pp. 895–898, 1999.
[59] W. Shen, B.Wu, Z. Zhang et al., “Activity-induced rapid synaptic
maturation mediated by presynaptic Cdc42 signaling,” Neuron,
vol. 50, no. 3, pp. 401–414, 2006.
[60] M.-G. Kang, Y. Guo, and R. L. Huganir, “AMPA receptor and
GEF-H1/Lfc complex regulates dendritic spine development
through RhoA signaling cascade,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 106, no.
9, pp. 3549–3554, 2009.
[61] Z. Xie, M. E. Cahill, and P. Penzes, “Kalirin loss results
in cortical morphological alterations,” Molecular and Cellular
Neuroscience, vol. 43, no. 1, pp. 81–89, 2010.
[62] P. Penzes, R. C. Johnson, R. Sattler et al., “The neuronal Rho-
GEF Kalirin-7 interacts with PDZ domain–containing proteins
and regulates dendritic morphogenesis,” Neuron, vol. 29, no. 1,
pp. 229–242, 2001.
[63] Z. Xie, D. P. Srivastava, H. Photowala et al., “Kalirin-7 controls
activity-dependent structural and functional plasticity of den-
dritic spines,” Neuron, vol. 56, no. 4, pp. 640–656, 2007.
[64] K. F. Tolias, J. B. Bikoff, A. Burette et al., “The Rac1-GEF
Tiam1 couples the NMDA receptor to the activity-dependent
development of dendritic arbors and spines,” Neuron, vol. 45,
no. 4, pp. 525–538, 2005.
[65] N. N. Kasri, A. Nakano-Kobayashi, R. Malinow, B. Li, and
L. Van Aelst, “The Rho-linked mental retardation protein
oligophrenin-1 controls synapse maturation and plasticity by
stabilizing AMPA receptors,” Genes & Development, vol. 23, no.
11, pp. 1289–1302, 2009.
[66] T. Sarowar, S. Grabrucker, K. Fo¨hr et al., “Enlarged dendritic
spines and pronounced neophobia in mice lacking the PSD
protein RICH2,”Molecular Brain, vol. 9, no. 1, article 28, 2016.
[67] K. Huang, “SYNGAP: bridging the gap between genetic factors
and autosomal non-syndromic mental retardation,” Clinical
Genetics, vol. 76, no. 2, pp. 149–151, 2009.
[68] A. S. Kim, L. T. Kakalis, N. Abdul-Manan, G. A. Liu, and M.
K. Rosen, “Autoinhibition and activation mechanisms of the
Wiskott–Aldrich syndrome protein,”Nature, vol. 404, no. 6774,
pp. 151–158, 2000.
[69] D.W. Leung, C. Otomo, J. Chory, andM. K. Rosen, “Genetically
encoded photoswitching of actin assembly through the Cdc42-
WASP-Arp2/3 complex pathway,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 105, no.
35, pp. 12797–12802, 2008.
[70] R. Rohatgi, L. Ma, H. Miki et al., “The interaction between N-
WASP and the Arp2/3 complex links Cdc42-dependent signals
to actin assembly,” Cell, vol. 97, no. 2, pp. 221–231, 1999.
[71] P. Steiner, M. J. Higley, W. Xu, B. L. Czervionke, R. C. Malenka,
and B. L. Sabatini, “Destabilization of the postsynaptic density
by PSD-95 Serine 73 phosphorylation inhibits spine growth and
synaptic plasticity,” Neuron, vol. 60, no. 5, pp. 788–802, 2008.
[72] H. D. Macgillavry, J. M. Kerr, J. Kassner, N. A. Frost, and T. A.
Blanpied, “Shank-cortactin interactions control actin dynamics
to maintain flexibility of neuronal spines and synapses,” Euro-
pean Journal of Neuroscience, vol. 43, no. 2, pp. 179–193, 2016.
[73] K. Han, J. L. Holder Jr., C. P. Schaaf et al., “SHANK3 overexpres-
sion causesmanic-like behaviourwith unique pharmacogenetic
properties,” Nature, vol. 503, no. 7474, pp. 72–77, 2013.
[74] H. N. Higgs and T. D. Pollard, “Regulation of actin filament
network formation through Arp2/3 complex: activation by a
diverse array of proteins,” Annual Review of Biochemistry, vol.
70, no. 1, pp. 649–676, 2001.
[75] S. Takeda, S. Minakata, R. Koike et al., “Two distinct mecha-
nisms for actin capping protein regulation—steric and allosteric
inhibition,” PLoS Biology, vol. 8, no. 7, Article ID e1000416, 2010.
[76] L. Van Aelst and C. D’Souza-Schorey, “Rho GTPases and
signaling networks,” Genes & Development, vol. 11, no. 18, pp.
2295–2322, 1997.
[77] R. J. Daly, “Cortactin signalling and dynamic actin networks,”
Biochemical Journal, vol. 382, no. 1, pp. 13–25, 2004.
[78] T. M. Bo¨ckers, M. G. Mameza, M. R. Kreutz et al., “Synaptic
scaffolding proteins in rat brain: ankyrin repeats of themultido-
main Shank protein family interact with the cytoskeletal protein
𝛼-fodrin,” The Journal of Biological Chemistry, vol. 276, no. 43,
pp. 40104–40112, 2001.
[79] S. Liebau, C. Proepper, T. Schmidt, M. Schoen, J. Bockmann,
and T. M. Boeckers, “ProSAPiP2, a novel postsynaptic density
protein that interacts with ProSAP2/Shank3,” Biochemical and
Biophysical Research Communications, vol. 385, no. 3, pp. 460–
465, 2009.
[80] B. Qualmann, T. M. Boeckers, M. Jeromin, E. D. Gundelfinger,
and M. M. Kessels, “Linkage of the actin cytoskeleton to the
postsynaptic density via direct interactions of Abp1 with the
ProSAP/Shank family,”The Journal of Neuroscience, vol. 24, no.
10, pp. 2481–2495, 2004.
[81] C. Proepper, S. Johannsen, S. Liebau et al., “Abelson interacting
protein 1 (Abi−1) is essential for dendrite morphogenesis and
synapse formation,”The EMBO Journal, vol. 26, no. 5, pp. 1397–
1409, 2007.
14 Neural Plasticity
[82] S.-M. Kim, K. Y. Choi, I. H. Cho et al., “Regulation of dendritic
spine morphology by SPIN90, a novel Shank binding partner,”
Journal of Neurochemistry, vol. 109, no. 4, pp. 1106–1117, 2009.
[83] I. H. Cho, D. H. Kim, M.-J. Lee, J. Bae, K. H. Lee, and W. K.
Song, “SPIN90 phosphorylation modulates spine structure and
synaptic function,” PLoS ONE, vol. 8, no. 1, Article ID e54276,
2013.
[84] S.-E. Lee, Y. Kim, J.-K. Han et al., “nArgBP2 regulates excitatory
synapse formation by controlling dendritic spine morphology,”
Proceedings of the National Academy of Sciences, vol. 113, no. 24,
pp. 6749–6754, 2016.
[85] J.-H. Tao-Cheng, Y. Yang, T. S. Reese, and A. Dosemeci, “Dif-
ferential distribution of shank and GKAP at the postsynaptic
density,” PLoS ONE, vol. 10, no. 3, Article ID e0118750, 2015.
[86] F. Raynaud, A. Janossy, J. Dahl et al., “Shank3-Rich2 interaction
regulates AMPA receptor recycling and synaptic long-term
potentiation,” The Journal of Neuroscience, vol. 33, no. 23, pp.
9699–9715, 2013.
[87] F. Raynaud, E. Moutin, S. Schmidt et al., “Rho-GTPase-
activating protein interacting with Cdc-42-interacting protein
4 homolog 2 (Rich2): a new ras-related C3 botulinum toxin sub-
strate1 (Rac1) GTPase-activating protein that controls dendritic
spine morphogenesis,”The Journal of Biological Chemistry, vol.
289, no. 5, pp. 2600–2609, 2014.
[88] E. Park, M. Na, J. Choi et al., “The Shank family of postsynaptic
density proteins interacts with and promotes synaptic accumu-
lation of the 𝛽PIX guanine nucleotide exchange factor for Rac1
and Cdc42,”The Journal of Biological Chemistry, vol. 278, no. 21,
pp. 19220–19229, 2003.
[89] D. Parnas, A. P. Haghighi, R. D. Fetter, S. W. Kim, and C. S.
Goodman, “Regulation of postsynaptic structure and protein
localization by the Rho-type guanine nucleotide exchange
factor dPix,” Neuron, vol. 32, no. 3, pp. 415–424, 2001.
[90] J. Bockmann, M. R. Kreutz, E. D. Gundelfinger, and T. M.
Bo¨ckers, “ProSAP/Shank postsynaptic density proteins interact
with insulin receptor tyrosine kinase substrate IRSp53,” Journal
of Neurochemistry, vol. 83, no. 4, pp. 1013–1017, 2002.
[91] M. Soltau, K. Berho¨rster, S. Kindler, F. Buck, D. Richter, and
H.-J. Kreienkamp, “Insulin receptor substrate of 53 kDa links
postsynaptic shank to PSD-95,” Journal of Neurochemistry, vol.
90, no. 3, pp. 659–665, 2004.
[92] D. Wendholt, C. Spilker, A. Schmitt et al., “ProSAP-interacting
protein 1 (ProSAPiP1), a novel protein of the postsynaptic
density that links the spine-associated Rap-Gap (SPAR) to the
scaffolding protein ProSAP2/Shank3,” The Journal of Biological
Chemistry, vol. 281, no. 19, pp. 13805–13816, 2006.
[93] D. T. S. Pak, S. Yang, S. Rudolph-Correia, E. Kim, andM. Sheng,
“Regulation of dendritic spinemorphology by SPAR, a PSD-95-
associated RapGAP,” Neuron, vol. 31, no. 2, pp. 289–303, 2001.
[94] C. Spilker, G. A. A. Sanhueza, T. M. Bo¨ckers, M. R. Kreutz, and
E. D. Gundelfinger, “SPAR2, a novel SPAR-related protein with
GAP activity for Rap1 andRap2,” Journal of Neurochemistry, vol.
104, no. 1, pp. 187–201, 2008.
[95] American Psychiatric Association, Diagnostic and Statistical
Manual—Text Revision (DSM-IV-TRim, 2000), American Psy-
chiatric Association, 2000.
[96] C. Betancur, “Etiological heterogeneity in autism spectrum
disorders:more than 100 genetic and genomic disorders and still
counting,” Brain Research, vol. 1380, pp. 42–77, 2011.
[97] C. Mullins, G. Fishell, and R. W. Tsien, “Unifying views of
autism spectrum disorders: a consideration of autoregulatory
feedback loops,” Neuron, vol. 89, no. 6, pp. 1131–1156, 2016.
[98] C. Bergmann, K. Zerres, J. Senderek et al., “Oligophrenin 1
(OPHN1) gene mutation causes syndromic X-linked mental
retardation with epilepsy, rostral ventricular enlargement and
cerebellar hypoplasia,” Brain, vol. 126, no. 7, pp. 1537–1544, 2003.
[99] P. Billuart, T. Bienvenu, N. Roncet et al., “Oligophrenin-
1 encodes a rhoGAP protein involved in X-linked mental
retardation,” Nature, vol. 392, no. 6679, pp. 923–926, 1998.
[100] V. Endris, B.Wogatzky,U. Leimer et al., “Thenovel Rho-GTPase
activating gene MEGAP/srGAP3 has a putative role in severe
mental retardation,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 99, no. 18, pp. 11754–
11759, 2002.
[101] E.-E. Govek, S. E. Newey, C. J. Akerman, J. R. Cross, L. Van
der Veken, and L. Van Aelst, “The X-linked mental retardation
protein oligophrenin-1 is required for dendritic spine morpho-
genesis,” Nature Neuroscience, vol. 7, no. 4, pp. 364–372, 2004.
[102] R. S. Devon, J. R. Helm, G. A. Rouleau et al., “The first
nonsense mutation in alsin results in a homogeneous pheno-
type of infantile-onset ascending spastic paralysis with bulbar
involvement in two siblings,”Clinical Genetics, vol. 64, no. 3, pp.
210–215, 2003.
[103] J. D. Topp, N. W. Gray, R. D. Gerard, and B. F. Horazdovsky,
“Alsin is a Rab5 and Rac1 guanine nucleotide exchange factor,”
The Journal of Biological Chemistry, vol. 279, no. 23, pp. 24612–
24623, 2004.
[104] Y. Yang, A. Hentati, H.-X. Deng et al., “The gene encoding
alsin, a protein with three guanine-nucleotide exchange factor
domains, is mutated in a form of recessive amyotrophic lateral
sclerosis,” Nature Genetics, vol. 29, no. 2, pp. 160–165, 2001.
[105] K. Kutsche, H. Yntema, A. Brandt et al., “Mutations in
ARHGEF6, encoding a guanine nucleotide exchange factor for
Rho GTPases, in patients with X-linked mental retardation,”
Nature Genetics, vol. 26, no. 2, pp. 247–250, 2000.
[106] G. J. A. Ramakers, D. Wolfer, G. Rosenberger et al., “Dysregu-
lation of Rho GTPases in the 𝛼Pix/Arhgef6 mouse model of X-
linked intellectual disability is paralleled by impaired structural
and synaptic plasticity and cognitive deficits,”HumanMolecular
Genetics, vol. 21, no. 2, pp. 268–286, 2012.
[107] N. N. Kasri and L. Van Aelst, “Rho-linked genes and neurologi-
cal disorders,” Pflu¨gers Archiv—European Journal of Physiology,
vol. 455, no. 5, pp. 787–797, 2008.
[108] T. Bienvenu, V. des Portes, N. McDonell et al., “Missense
mutation in PAK3, R67C, causes X-linked nonspecific mental
retardation,” American Journal of Medical Genetics, vol. 93, no.
4, pp. 294–298, 2000.
[109] B. Bardoni and J.-L. Mandel, “Advances in understanding of
fragile X pathogenesis and FMRP function, and in identification
of X linked mental retardation genes,” Current Opinion in
Genetics & Development, vol. 12, no. 3, pp. 284–293, 2002.
[110] F. Tassone, R. J. Hagerman, D. N. Ikle´ et al., “FMRP expression
as a potential prognostic indicator in fragile X syndrome,”
American Journal of Medical Genetics, vol. 84, no. 3, pp. 250–
261, 1999.
[111] P. Penzes, K. M. Woolfrey, and D. P. Srivastava, “Epac2-
mediated dendritic spine remodeling: implications for disease,”
Molecular and Cellular Neuroscience, vol. 46, no. 2, pp. 368–380,
2011.
[112] D. P. Srivastava, K. M. Woolfrey, K. A. Jones et al., “An
autism-associated variant of Epac2 reveals a role for Ras/Epac2
signaling in controlling basal dendrite maintenance in mice,”
PLoS Biology, vol. 10, no. 6, Article ID e1001350, 2012.
Neural Plasticity 15
[113] K. M. Woolfrey, D. P. Srivastava, H. Photowala et al., “Epac2
induces synapse remodeling and depression and its disease-
associated forms alter spines,” Nature Neuroscience, vol. 12, no.
10, pp. 1275–1284, 2009.
[114] M. H. Berryer, F. F. Hamdan, L. L. Klitten et al., “Mutations
in SYNGAP1 cause intellectual disability, autism, and a specific
form of epilepsy by inducing haploinsufficiency,”HumanMuta-
tion, vol. 34, no. 2, pp. 385–394, 2013.
[115] G. L. Carvill, S. B. Heavin, S. C. Yendle et al., “Targeted
resequencing in epileptic encephalopathies identifies de novo
mutations in CHD2 and SYNGAP1,” Nature Genetics, vol. 45,
no. 7, pp. 825–830, 2013.
[116] F. F. Hamdan, H. Daoud, A. Piton et al., “De novo SYNGAP1
mutations in nonsyndromic intellectual disability and autism,”
Biological Psychiatry, vol. 69, no. 9, pp. 898–901, 2011.
[117] F. F. Hamdan, J. Gauthier, D. Spiegelman et al., “Mutations in
SYNGAP1 in autosomal nonsyndromicmental retardation,”The
New England Journal of Medicine, vol. 360, no. 6, pp. 599–605,
2009.
[118] C. S. Leblond, C.Nava, A. Polge et al., “Meta-analysis of SHANK
mutations in autism spectrum disorders: a gradient of severity
in cognitive impairments,” PLoS Genetics, vol. 10, no. 9, Article
ID e1004580, 2014.
[119] K. Phelan and H. E. McDermid, “The 22q13.3 deletion syn-
drome (Phelan-McDermid syndrome),” Molecular Syndromol-
ogy, vol. 2, no. 3-5, pp. 186–201, 2012.
[120] H. L. Wilson, A. C. C. Wong, S. R. Shaw et al., “Molecular
characterisation of the 22q13 deletion syndrome supports the
role of haploinsufficiency of SHANK3/PROSAP2 in the major
neurological symptoms,” Journal ofMedical Genetics, vol. 40, no.
8, pp. 575–584, 2003.
[121] P. Penzes, M. E. Cahill, K. A. Jones, J.-E. Vanleeuwen, and K.
M. Woolfrey, “Dendritic spine pathology in neuropsychiatric
disorders,”Nature Neuroscience, vol. 14, no. 3, pp. 285–293, 2011.
[122] J. J. Hutsler and H. Zhang, “Increased dendritic spine densities
on cortical projection neurons in autism spectrum disorders,”
Brain Research, vol. 1309, pp. 83–94, 2010.
[123] A. Y. Hung, K. Futai, C. Sala et al., “Smaller dendritic spines,
weaker synaptic transmission, but enhanced spatial learning in
mice lacking Shank1,”The Journal of Neuroscience, vol. 28, no. 7,
pp. 1697–1708, 2008.
[124] J. L. Silverman, S. M. Turner, C. L. Barkan et al., “Sociability and
motor functions in Shank1 mutant mice,” Brain Research, vol.
1380, pp. 120–137, 2011.
[125] M.Wo¨hr, F. I. Roullet, A. Y. Hung, M. Sheng, and J. N. Crawley,
“Communication impairments inmice lacking Shank1: reduced
levels of ultrasonic vocalizations and scent marking behavior,”
PLoS ONE, vol. 6, no. 6, Article ID e20631, 2011.
[126] M. J. Schmeisser, E. Ey, S. Wegener et al., “Autistic-like
behaviours and hyperactivity inmice lacking ProSAP1/Shank2,”
Nature, vol. 486, no. 7402, pp. 256–260, 2012.
[127] E.-J. Lee, H. Lee, T.-N. Huang et al., “Trans-synaptic zinc mobi-
lization improves social interaction in two mouse models of
autism through NMDAR activation,” Nature Communications,
vol. 6, article no. 7168, 2015.
[128] H. Won, H.-R. Lee, H. Y. Gee et al., “Autistic-like social
behaviour in Shank2-mutant mice improved by restoring
NMDA receptor function,” Nature, vol. 486, no. 7402, pp. 261–
265, 2012.
[129] X. Wang, A. L. Bey, B. M. Katz et al., “Altered mGluR5-Homer
scaffolds and corticostriatal connectivity in a Shank3 complete
knockout model of autism,” Nature Communications, vol. 7,
Article ID 11459, 2016.
[130] L. J. Duffney, P. Zhong, J. Wei et al., “Autism-like deficits in
Shank3-deficient mice are rescued by targeting actin regula-
tors,” Cell Reports, vol. 11, no. 9, pp. 1400–1413, 2015.
[131] G. Roussignol, F. Ango, S. Romorini et al., “Shank expression
is sufficient to induce functional dendritic spine synapses in
aspiny neurons,”The Journal of Neuroscience, vol. 25, no. 14, pp.
3560–3570, 2005.
[132] M. G. Mameza, E. Dvoretskova, M. Bamann et al., “SHANK3
gene mutations associated with autism facilitate ligand binding
to the Shank3 ankyrin repeat region,” The Journal of Biological
Chemistry, vol. 288, no. 37, pp. 26697–26708, 2013.
[133] R. K. Carlin, D. C. Bartelt, and P. Siekevitz, “Identification of
fodrin as a major calmodulin-binding protein in postsynaptic
density preparations,”The Journal of Cell Biology, vol. 96, no. 2,
pp. 443–448, 1983.
[134] S. Lim, C. Sala, J. Yoon et al., “Sharpin, a novel postsynaptic
density protein that directly interacts with the shank family of
proteins,”Molecular and Cellular Neuroscience, vol. 17, no. 2, pp.
385–397, 2001.
[135] C. M. Durand, J. Perroy, F. Loll et al., “SHANK3 mutations
identified in autism lead to modification of dendritic spine
morphology via an actin-dependent mechanism,” Molecular
Psychiatry, vol. 17, no. 1, pp. 71–84, 2012.
[136] O. Bozdagi, T. Sakurai, D. Papapetrou et al., “Haploinsufficiency
of the autism-associated Shank3 gene leads to deficits in synap-
tic function, social interaction, and social communication,”
Molecular Autism, vol. 1, no. 1, article 15, 2010.
[137] M. Yang, O. Bozdagi, M. L. Scattoni et al., “Reduced excitatory
neurotransmission and mild Autism-Relevant phenotypes in
adolescent shank3 null mutant mice,” The Journal of Neuro-
science, vol. 32, no. 19, pp. 6525–6541, 2012.
[138] X. Wang, P. A. McCoy, R. M. Rodriguiz et al., “Synaptic
dysfunction and abnormal behaviors in mice lacking major
isoforms of Shank3,”Human Molecular Genetics, vol. 20, no. 15,
pp. 3093–3108, 2011.
[139] J. Pec¸a, C. Feliciano, J. T. Ting et al., “Shank3 mutant mice dis-
play autistic-like behaviours and striatal dysfunction,” Nature,
vol. 472, no. 7344, pp. 437–442, 2011.
Submit your manuscripts at
http://www.hindawi.com
Neurology 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Alzheimer’s Disease
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Scientifica
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
Schizophrenia
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Neural Plasticity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
Autism
Sleep Disorders
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Neuroscience 
Journal
Epilepsy Research 
and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Psychiatry 
Journal
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Depression Research 
and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Brain Science
International Journal of
Stroke
Research and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Neurodegenerative 
Diseases
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Cardiovascular Psychiatry 
and Neurology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
